Prolonged wear of facial protective equipment can lead to occupational dermatoses.To identify important causes of occupational dermatoses from facial protective equipment.A systematic review following PRISMA guidelines was performed using PubMed …
Cutaneous toxicities in melanoma patients receiving checkpoint inhibitor therapy, a retrospective review: The experience of a single large specialist institution.
CPI was approved by the European Medicines Agency (EMA) in 2012 for advanced melanoma and extended to include adjuvant melanoma treatment in 2018. Expectation for survival in advanced melanoma now …
Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis a multicenter, double-blind, randomized controlled study.
Capsule summary Despite the absence of robust evidence, tacrolimus is quite commonly used off label as maintenance treatment for seborrheic dermatitis, in clinical practice. Tacrolimus 0.1% ointment applied twice a …
Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial.
Dysbiosis and colonization with Staphylococcus aureus is considered to play an important role in the pathogenesis of atopic dermatitis (AD). Recovering this dysbiosis may improve AD symptoms. Omiganan is a …
Comparison of efficacy of noncultured hair follicle cell suspension and noncultured epidermal cell suspension in repigmentation of leukotrichia and skin patch in vitiligo: a randomized trial.
Vitiligo manifests as hypo- to de-pigmented macules, which are sometimes associated with leukotrichia. For complete cosmetic improvement, the repigmentation of leukotrichia is an important component.This randomized controlled trial included patients …
Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.
Atopic dermatitis (AD) is an allergic disease that affects individuals of various ages. Recently, the IL-4/13 inhibitor dupilumab has gained regulatory approval for clinical use in AD patients. Dupilumab has …
Plasma Caffeine Concentration Lower in Parkinson Disease
Results similar for caffeine metabolites and non-xanthine marker for coffee consumption in plasma
Antibodies Decrease With Time After COVID-19 Symptom Onset
For all donors of convalescent plasma, drop seen in anti-RBD antibody levels from first to last donation
Mortality Risk Up With Newer Antipsychotic Use for Depression
Risk up for nonelderly adults with augmentation with newer antipsychotic versus second antidepressant
Outcomes Worse for Deferred Aortic Valve Replacement
Mortality, stroke, hospitalization seen in 19.1 and 4.0 percent with deferred versus expedited AVR